Hla Typing in Epidermolysis Bullosa Patients: Relevancy to Gluten Sensitivity
- *Corresponding Author:
- Dr. Giuseppina Annicchiarico
Regional coordination for rare diseases - Ares Puglia
Via Caduti di tutte le Guerre 15, 70125 Bari, Italy
Tel: 0039080 9188139
E-mail: [email protected]
Received date: July 31, 2013; Accepted date:September 21, 2013; Published date: September 29, 2013
Citation: Annicchiarico G, Morgese MG, Fiore T, Mauro S, Garofalo L, et al. (2013) Hla Typing in Epidermolysis Bullosa Patients: Relevancy to Gluten Sensitivity. J Genet Syndr Gene Ther 4:182. doi:10.4172/2157-7412.1000182
Copyright: © 2013 Annicchiarico G, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Background: Epidermolysis bullosa (EB) is an inherited genetic disease affecting skin adhesion at dermal or epidermal level or in the basement membrane zone. EB is present in three major forms: simplex, junctional and dystrophic. This latter is very often associated to non-cutaneous manifestation such as gastrointestinal complication and renal damage. Aim of this study was to classify EB patients based on an assigned severity score and individuate precipitating factor, such as HLA predisposing to gluten sensitivity, responsible of the different course of the extracutaneous manifestation of the pathology. Methods: By using a cross sectional design, 36 EB patients were screened based on the Birmingham severity score and HLA typing was performed in order to discover possible associations. HLA typing test was performed by PCR and statistical method of analysis was the χ2 test. Controls (n=341) were healthy volunteer subjects. Results: From a total of 36 patients, 24 were diagnosed of the more sever form of EB, the dystrophic one. The assigned scores ranged from 11 to 90, while the 12 simplex patients received a score from 0-2. In regard to HLA typing, we found that in EB patients the 21.62% expressed a DQ2.2 HLA, while controls only 5.87% (P<0.0005 χ2 test). No statistically significant difference was found among the other aplotypes. Conclusion: Although, no difference was found in regard to HLA-DQ2.5, the strongest aplotype associated to celiac disease, we found that in EB patient there was a higher incidence of HLA-DQ2.2 that in a condition of chronic intestinal inflammation, as in these patients is likely to be, may predispose to sensitivity to gluten ultimately leading to immune mediated-organ damage.